{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/deep-vein-thrombosis/prescribing-information/oral-anticoagulants/","result":{"pageContext":{"chapter":{"id":"7e7201d1-4e56-53ec-95ac-c64ea70060e4","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants","depth":2,"htmlHeader":"<!-- begin field c989730c-fc60-4cda-8ed3-ab3b008e36cd --><h2>Oral anticoagulants</h2><!-- end field c989730c-fc60-4cda-8ed3-ab3b008e36cd -->","summary":"","htmlStringContent":"<!-- begin item 5afe0d5f-c2a2-41a7-9f40-ab3b008e361e --><!-- begin field 33530653-036b-42ee-8518-ab3b00f9ae35 --><ul><li>The direct oral anticoagulants (DOACs) licensed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults are:<ul><li>Apixaban.</li><li>Dabigatran.</li><li>Edoxaban.</li><li>Rivaroxaban.</li></ul></li><li>Warfarin is also licensed for the treatment and prophylaxis of DVT and PE. </li><li>For detailed prescribing information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">NICE, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">NICE, 2015b</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">NICE, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2018b</a>]</p><!-- end field 33530653-036b-42ee-8518-ab3b00f9ae35 --><!-- end item 5afe0d5f-c2a2-41a7-9f40-ab3b008e361e -->","topic":{"id":"c1b45e75-436b-56a1-a385-f8422d715e82","topicId":"a4df6bb3-1690-4ec4-9cba-0dcff60cc7ef","topicName":"Deep vein thrombosis","slug":"deep-vein-thrombosis","lastRevised":"Last revised in November 2020","chapters":[{"id":"043e731c-3abf-53ee-a31d-8d884bd3bc70","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bf477005-0407-58ad-9621-2529440a1912","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0d6b5798-088f-5468-84b7-a93cfe9e70d4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c5e88810-6d89-56ef-9120-966cbdac34da","slug":"changes","fullItemName":"Changes"},{"id":"06d2c305-090e-5332-b7a1-b6be267bcd41","slug":"update","fullItemName":"Update"}]},{"id":"0e61afec-aecd-50f3-8f6d-ef8da1dc9003","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"acd9fd74-ef09-56e2-b4e4-65e22ddc6269","slug":"goals","fullItemName":"Goals"},{"id":"13b37b76-163e-58e7-9ed4-add17978eb23","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c283b01d-3860-51e0-bb61-d68a12c34e68","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6c0366d1-9980-5dc1-8946-44e5030bc691","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"707aca3b-1b4f-52aa-848d-6d44d4337f41","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9b9c8c09-f068-59bc-ad89-ca508289d1b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"341b7f8d-b4d0-58b0-8198-4c563cb9f40e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b31fd103-9bbb-5216-ad96-7ce04f610584","slug":"definition","fullItemName":"Definition"},{"id":"f95afcb9-845a-579a-a5bd-b95f7163d1b9","slug":"incidence","fullItemName":"Incidence"},{"id":"fb6ff0cb-ba3b-5075-9e5e-52380bc0ecd3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b828ffa2-5a2d-5a7d-89c2-3b5ce4c27b07","slug":"complications","fullItemName":"Complications"}]},{"id":"837dc43f-aac0-51fa-af65-afb4b7a54467","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"699e0a9f-a13f-535b-91e2-967968d57b5e","slug":"when-to-suspect-dvt","fullItemName":"When to suspect DVT"},{"id":"e436c043-ce99-5fc5-b99e-deb107b997e9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9caf86d2-a390-5cb8-bcec-dd055468ba41","fullItemName":"Management","slug":"management","subChapters":[{"id":"edd98243-d8d1-5402-a55c-9d8de8e68068","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"02795cd7-4068-5ef2-840c-914a96cfd71b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"15bc2153-6b1c-5a58-9c8d-25d9978f2dde","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants"},{"id":"7e7201d1-4e56-53ec-95ac-c64ea70060e4","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants"}]},{"id":"a5e9e695-9150-5486-8075-1fa6c8b75fba","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06671f87-530c-52a1-800c-749cdb70cad7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"63cf38fe-dc13-5253-93e7-bb3da5b958a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"439fde91-9bb2-561f-8d66-de440bc5e387","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0f076b49-f0f3-597a-ba30-f5f3f414beae","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5e81047f-a3c4-52f4-ad24-f951952ea809","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"17391681-76bf-5417-9a9c-6e66245c631d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2cd34860-5410-5109-8de9-0227c8af1e62","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"02795cd7-4068-5ef2-840c-914a96cfd71b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"4dbf15a5-3182-5aba-878e-7bc3b52f7522","slug":"apixaban","fullItemName":"Apixaban","depth":3,"htmlHeader":"<!-- begin field efac679e-aafe-48ff-a48c-ab3b008e4374 --><h3>What should I be aware of when prescribing apixaban?</h3><!-- end field efac679e-aafe-48ff-a48c-ab3b008e4374 -->","summary":"","htmlStringContent":"<!-- begin item e26bd8ed-6572-4fa7-9433-ab3b008e4336 --><!-- begin field 0917c5f4-2770-47d0-9f94-ab3b008e4374 --><ul><li>Apixaban should be taken orally.</li><li>The recommended dose of apixaban for the treatment of deep vein thrombosis is 10 mg twice daily for 7 days, followed by a maintenance dose of 5 mg twice daily.</li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/\">Apixaban</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 0917c5f4-2770-47d0-9f94-ab3b008e4374 --><!-- end item e26bd8ed-6572-4fa7-9433-ab3b008e4336 -->","subChapters":[]},{"id":"2a92c4f6-d29a-587d-8d75-d3d70637ce35","slug":"rivaroxaban","fullItemName":"Rivaroxaban","depth":3,"htmlHeader":"<!-- begin field ea640f70-9121-424e-a52a-ab3b0091ee15 --><h3>What should I be aware of when prescribing rivaroxaban?</h3><!-- end field ea640f70-9121-424e-a52a-ab3b0091ee15 -->","summary":"","htmlStringContent":"<!-- begin item 0d314a75-9d8b-4100-99fc-ab3b0091ed0f --><!-- begin field 0df3538c-10d2-4bd6-b80d-ab3b0091ee15 --><ul><li>Rivaroxaban should be taken orally with food.  </li><li>The recommended dose of rivaroxaban for the treatment of deep vein thrombosis is 15 mg twice daily (on days 1–21), followed by a maintenance dose of 20 mg once daily.</li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/rivaroxaban/\">Rivaroxaban</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>. </li><li>Rivaroxaban is a black triangle drug and is subject to additional monitoring. </li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">MHRA, 2019</a>]</p><!-- end field 0df3538c-10d2-4bd6-b80d-ab3b0091ee15 --><!-- end item 0d314a75-9d8b-4100-99fc-ab3b0091ed0f -->","subChapters":[]},{"id":"4479caea-d4bc-57a8-a3d0-637429411b15","slug":"dabigatran","fullItemName":"Dabigatran","depth":3,"htmlHeader":"<!-- begin field a0629752-e78e-48c7-8579-ab3b01015066 --><h3>What should I be aware of when prescribing dabigatran?</h3><!-- end field a0629752-e78e-48c7-8579-ab3b01015066 -->","summary":"","htmlStringContent":"<!-- begin item 46dfdefe-56b3-42c0-9f24-ab3b0101503f --><!-- begin field 1499ceb0-2831-462d-bc61-ab3b01015066 --><ul><li>The recommended dose of dabigatran for the treatment of deep vein thrombosis (following treatment with a parenteral anticoagulant for at least 5 days) is:<ul><li>150 mg twice daily in people aged 18–74 years.</li><li>110 to 150 mg twice daily in people aged 75–79 years.</li><li>110 mg twice daily in people aged 80 years and over.</li></ul></li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/dabigatran/\">Dabigatran</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2019e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 1499ceb0-2831-462d-bc61-ab3b01015066 --><!-- end item 46dfdefe-56b3-42c0-9f24-ab3b0101503f -->","subChapters":[]},{"id":"da7fcea5-3fde-5b5a-b149-59374be57ee0","slug":"edoxaban","fullItemName":"Edoxaban","depth":3,"htmlHeader":"<!-- begin field 5b455575-2a20-4cd2-9e23-ab3b01015db5 --><h3>What should I be aware of when prescribing edoxaban?</h3><!-- end field 5b455575-2a20-4cd2-9e23-ab3b01015db5 -->","summary":"","htmlStringContent":"<!-- begin item 9efb1333-7019-4356-8dd1-ab3b01015d8e --><!-- begin field 86bc7bb4-19a0-4b48-b745-ab3b01015db5 --><ul><li>The recommended dose of edoxaban for the treatment of deep vein thrombosis is 60 mg once daily (30 mg once daily in people with body weight of 61 kg or less) following initial use of parenteral anticoagulant for at least 5 days.</li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/\">Edoxaban</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>. </li><li>Edoxaban is a black triangle drug and is subject to additional monitoring. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 86bc7bb4-19a0-4b48-b745-ab3b01015db5 --><!-- end item 9efb1333-7019-4356-8dd1-ab3b01015d8e -->","subChapters":[]},{"id":"b16d5ec4-4499-5445-8725-4ed2f4b8bbc0","slug":"warfarin","fullItemName":"Warfarin","depth":3,"htmlHeader":"<!-- begin field dd1fc08d-8201-4e66-8365-ab3c00bf6fd9 --><h3>What should I be aware of when prescribing warfarin?</h3><!-- end field dd1fc08d-8201-4e66-8365-ab3c00bf6fd9 -->","summary":"","htmlStringContent":"<!-- begin item 9a474a1d-b276-4623-96e8-ab3c00bf6f63 --><!-- begin field b5fd6bc5-be2b-4a84-bbc4-ab3c00bf6fd9 --><ul><li>Warfarin should be started within 24 hours of confirmed proximal deep vein thrombosis and is taken orally in combination with a parenteral anticoagulant — low molecular weight heparin (LMWH) or fondaparinux. <ul><li>The LMHW or fondaparinux is started as soon as possible and continued for at least 5 days, or until the international normalised ratio (INR) is 2 or above for at least 24 hours, whichever is longer, and the warfarin continued for at least 3 months.</li></ul></li><li>The typical induction dose of warfarin is 10 mg daily for 2 days, and the daily maintenance dose is usually 3 mg to 9 mg taken at the same time each day. However, doses should be tailored depending on the person's INR. </li><li>For detailed prescribing information, including contraindications, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/management/warfarin/\">Warfarin</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">NICE, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field b5fd6bc5-be2b-4a84-bbc4-ab3c00bf6fd9 --><!-- end item 9a474a1d-b276-4623-96e8-ab3c00bf6f63 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}